Abstract: A film forming device includes: a microwave supplying unit configured to supply microwave pulses to generate plasma along a processing surface of a workpiece material; an applying unit configured to apply negative bias voltage pulses to spread a sheath layer along the processing surface of the workpiece material, and a control unit configured to control an applying timing of the negative bias voltage pulses and a supplying timing of the microwave pulses, wherein the control unit is configured to control the applying timing of the negative bias voltage pulses and the supplying timing of the microwave pulses so that a ratio of an applying time period of one negative bias voltage pulse in a supplying time period of one microwave pulse to the supplying time period of one microwave pulse is equal to or greater than 0.9.

Abstract: A force sensor according to embodiments includes a light-emitting unit, a pair of first light detectors, a reflector, and a first frame. The light-emitting unit emits diffuse light. The first light detectors are arranged in a first direction with the light-emitting unit interposed therebetween. The reflector is arranged to face the light-emitting unit on an optical axis of the light-emitting unit and reflects the diffuse light emitted from the light-emitting unit toward the first light detectors. The first frame is deformed in the first direction so that a reflection range of the diffuse light reflected by the reflector is displaced in the first direction.

Abstract: The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect.

Abstract: To provide a transformation method for producing a stramenopile organism having an improved unsaturated fatty acid production capability by disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner. [Solution] A method for transforming a stramenopile organism, which comprises disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner, and which is characterized in that the stramenopile organism is selected from Thraustochytrium aureum, Parietichytrium sarkarianum, Thraustochytrium roseum and Parietichytrium sp. and the gene to be disrupted or of which the expression is to be inhibited is a gene associated with the biosynthesis of a fatty acid.

Abstract: [PROBLEM] There is provided a broadband infrared light emitting device that radiates infrared light having a band broader than a conventional broadband infrared light emitting device.

Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Abstract: A charged particle irradiation system is capable of shortening the irradiation time and the treatment time by performing efficient irradiation even when irregular variation occurs in the irradiation object during the gating irradiation. The extraction of the beam is stopped upon reception of a regular extraction permission end signal which is outputted based on a regular movement signal. An extractable state maintaining function operates upon the reception of the extraction permission end signal. When a preset standby time elapses without receiving an extraction permission start signal again during the standby time, the extractable state maintaining function finishes its operation and a charged particle beam generator decelerates the beam. Also, the extraction of the beam is stopped due to reception of an irregular extraction permission end signal during the irradiation. When the extraction permission start signal is received again during the standby time, the extraction of the beam is restarted.

Abstract: The present invention is intended to provide an artificial polyclonal immunoglobulin composition or artificial immunoglobulin fragment composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other. An artificial immunoglobulin fragment composition is also provided that can include at least one polypeptide comprising an amino acid sequence set forth in SEQ ID NOS: 1 to 204, for example, SEQ ID NO. 31.

Abstract: Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof.

Abstract: A liquid medicine of the present invention comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection, and a method of treatment of the present invention using a liquid medicine comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection can reduce or eliminate tumors with few side effects. When the liquid medicine of the present invention comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection, and the method of treatment of the present invention using a liquid medicine comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection are used in combination with surgical therapy, chemotherapy, radiotherapy, or immunotherapy of tumors, effects can be enhanced or side effects can be reduced compared with monotherapy or multidisciplinary therapy thereof.

Abstract: Fluorescence-emitting material which improves luminous efficiency of an organic light-emitting element such as an organic EL element or an organic PL element and an organic light-emitting element using the fluorescence-emitting material. The fluorescence-emitting material includes a compound having an indolocarbazole skeleton represented by the following general formula (1), as defined in the specification. The organic light-emitting element includes an organic EL element including: a substrate; an anode; a cathode; and a light-emitting layer, the anode and the cathode being laminated on the substrate and the light-emitting layer being sandwiched between the anode and the cathode, in which the light-emitting layer includes: the organic light-emitting material; and as a host material, an organic compound having excited triplet energy higher than that of the organic light-emitting material.

Abstract: PAH is subjected to C—H/C—B coupling using a specific boron compound, a palladium compound, and o-chloranil to produce a compound in which a C—H bond of the PAH is directly arylated regioselectively in a simple manner. When the substrate and the boron compound are appropriately selected, a larger PAH can also be obtained by further performing an annulation reaction after the coupling reaction. Similarly, when PAH is subjected to C—H/C—H cross-coupling using a specific aromatic compound, a palladium compound, and o-chloranil, a compound in which a C—H bond of the PAH is directly arylated regioselectively can be produced in a simple manner. When the substrate and the aromatic compound are appropriately selected in this case, a larger PAH can also be obtained by further performing an annulation reaction after the cross-coupling reaction.

Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: To provide a method capable of producing stereocomplex polylactic acid, the method being capable of using carbon neutral materials that are not competitive from foods, such as saccharides, without the use of a method for designing optical resolution, which requires complicated operations and high cost and is difficult to perform mass production. The production method of the present invention comprises: a step of reacting glycerin with sodium hydroxide in high-temperature and high-pressure water to produce a racemic sodium lactate aqueous solution; a step of separating sodium from the racemic sodium lactate aqueous solution to recover racemic lactic acid; a step of dimerizing the racemic lactic acid to produce a lactide mixture containing meso lactide and racemic lactide; a step of separating meso lactide from the mixture to recover racemic lactide; and a step of polymerizing the racemic lactide with a salen-metal complex as a catalyst to produce stereocomplex polylactic acid.

Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.

Abstract: Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the 8-position of coelenterazine and coelenteramide analogs modified at the 2- or 3-position of coelenteramide.

Abstract: A golf ball 2 has numerous craters 8 on its surface. The craters 8 are arranged randomly. Of the surface of the golf ball 2, a part other than the craters 8 is a land 10. By the craters 8 and the land 10, a rugged pattern is formed on the golf ball 2. A process for designing the rugged pattern includes the steps of: (1) assuming a plurality of states; (2) assuming a large number of cells on a spherical surface; (3) deciding an initial state of each cell; (4) determining whether or not to change a state of the each cell based on states of a plurality of cells located adjacent to the each cell; (5) updating the state of the each cell based on the determination; and (6) assigning a land 10 or a recess to the each cell according to the state of the each cell.

Abstract: The purpose of the present invention is to provide: a biomarker specific to lymphocytic infundibuloneurohypophysitis; and use applications of the biomarker. Provided are: a biomarker comprising an anti-rabphilin 3a antibody; and a test method using the biomarker.

Abstract: Provided is an adsorption refrigerator that achieves high cooling capacity while reducing the volume the device as a whole occupies. The adsorption refrigerator according to the present embodiment has a configuration in which only one adsorption reactor is positioned directly above a first lower-layer adsorption reactor and a second lower-layer adsorption reactor. In addition, the adsorption refrigerator according to the present embodiment performs sequence control in which one of the first lower-layer adsorption reactor and the second lower-layer adsorption reactor keeps performing an adsorption process, whereas the other one changes processes of preheating, desorption, precooling, and adsorption.

Abstract: Using a device for producing nanocarbon, a fluidized bed is formed by supplying a low hydrocarbon and oxygen to a fluid catalyst, and nanocarbon and hydrogen are produced by a decomposition reaction of the low hydrocarbon accompanied by a self-combustion of the low hydrocarbon and the oxygen. The device includes: a fluidized bed reactor for containing the fluid catalyst and for causing the self-combustion thereof while being supplied with the low hydrocarbon and the oxygen; a gas supplying unit connected to the fluidized bed reactor for supplying the low hydrocarbon and the oxygen to the fluidized bed reactor; an exhaust gas path connected to the fluidized bed reactor for exhausting an exhaust gas in the fluidized bed reactor to outside; and a supplying unit connected to the fluidized bed reactor for supplying the fluid catalyst to the fluidized bed reactor.